Skip to main content
Top
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

Impact of mammographic screening in New South Wales

Author: Jenny McCann

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

Organised mammographic screening for breast cancer was introduced in New South Wales (NSW) Australia in 1988, starting with two pilot projects. Screening was extended throughout the state from 1991 with most areas covered by 1994. The goal of the programme is to reduce breast cancer deaths in the target age group (50-69 years) by 30%. As screening is introduced, a large increase in incidence of early breast cancers should be observed which should then be followed by a decrease in advanced cancer incidence. This in turn should lead to a reduction in mortality. An increase in the proportion of small tumours occurring after the introduction of screening has already been reported. Changes in advanced cancer incidence and breast cancer mortality rates are now presented. …
Literature
1.
go back to reference Kricker A, Farac K, Smith D, Sweeny A, McCredie M, Armstrong BK: Breast cancer in New South Wales in 1972-95: tumour size and the impact of mammographic screening. Int J Cancer. 1999, 81: 877-880.CrossRefPubMed Kricker A, Farac K, Smith D, Sweeny A, McCredie M, Armstrong BK: Breast cancer in New South Wales in 1972-95: tumour size and the impact of mammographic screening. Int J Cancer. 1999, 81: 877-880.CrossRefPubMed
Metadata
Title
Impact of mammographic screening in New South Wales
Author
Jenny McCann
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66587

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine